2021 Related Topics 
STAT
JANUARY 13, 2025
DNA sequencer manufacturer Illumina has also invested $20 million in the project, which builds on a 2021 investment and partnership from Microsoft, which will provide the cloud infrastructure for the project. Pharmaceutical company Regeneron has invested $119.5 Continue to STAT+ to read the full story…
STAT
OCTOBER 31, 2024
Between 2017 and 2021, regulators in the U.S. Of 104 reports of supply chain issues with dozens of drugs, meaningful shortages were 40% less likely to occur in Canada than in the U.S., a new study found, and the difference was largely attributed to the approach taken by the Canadian government to the problem.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
APRIL 16, 2025
After the world’s largely disastrous response to the coronavirus, countries tasked the WHO with overseeing a pandemic treaty in 2021; negotiations concluded early Wednesday on an agreement expected to be adopted next month at the U.N. health agency’s annual meeting in Geneva. Read the rest…
STAT
FEBRUARY 12, 2025
In 2021, the company spun out Isomorphic Labs, an AI drug discovery company. The Alphabet-owned AI company took the biology world by storm in 2020 with AlphaFold2 , the protein structure prediction AI platform that “solved” a decades-old biology problem.
STAT
APRIL 7, 2025
Medicare Advantage insurers pulled in an estimated $33 billion in additional payment from the government in 2021 as a result of these extra diagnoses, or codes, that made their members seem sicker, relative to people in the traditional Medicare program.
Pharmaceutical Technology
JUNE 9, 2025
Analysis includes innovative medicines with approved indications or indication extensions that were reimbursed since 2021. On average, 58% of branded drugs approved between 2021 and 2024 in Europe have either fully or restricted reimbursement. Patient profiles were counted distinctly.
STAT
APRIL 28, 2025
In 2021, for instance, 59% of companies scored highly, compared with 41% in 2018. The back-to-back declines come after 60% of patient groups believed the industry fared well thanks to the initial response of many companies to quickly develop salves for the Covid-19 pandemic. Continue to STAT+ to read the full story…
Expert insights. Personalized for you.
335 
Let's personalize your content